The APOKONNECT project selected by the Regional Health Agency, the Auvergne Rhône-Alpes region and Bpifrance, will combine the expertise of BIOCORP and Aguettant to improve the medical care and follow-up of patients suffering from Parkinson’s disease.
BIOCORP, a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announces the launch of APOKONNECT in partnership with Aguettant, laboratory specialized in the development, manufacturing and commercialization of essential medicines for hospitals.
The APOKONNECT project selected by the Regional Health Agency, the Auvergne Rhône-Alpes region and Bpifrance, will combine the expertise of BIOCORP and Aguettant to improve the medical care and follow-up of patients suffering from Parkinson’s disease.
The Parkinson’s disease is a chronic neurodegenerative disease with disabling motor symptoms, which affects around 200,000 people in France (25,000 new cases diagnosed each year). Its therapeutic care is complex and requires high intensity care, especially in the case of motor fluctuations and demands a regular patient monitoring.
The innovative APOKONNECT project will rely both on APOKINON, an apomorphine self-injection pen developed by Aguettant, and on Easylog, the connected device developed by BIOCORP. By connecting patients to healthcare professionals involved in the treatment, it will enable improvements of the patient’s medical care and ease the follow-up of the ambulatory treatment by apomorphine.
By gathering data related to patients’ treatment and symptoms on a tablet computer or smartphone though a secured app, this innovative treatment will not only help improve the treatment compliance and patients’ life, but it will also increase their autonomy and lead to the development of “homecare” while staying connected to healthcare professional in real-time.
The study, carried out within the framework of the APOKONNECT project, will run for 19 months and include the system integration, different studies to assess the daily use and the preparation of the deployment. The tests, firstly undertaken at a regional level, will then be deployed on a larger scale.
Financed by the Regional intervention fund of the Auvergne-Rhône-Alpes region, the Innovation Fund of Rhône-Alpes, namely the Social Innovation Funds and Bpifrance’s financial apparatus, the project will widely contribute to the industrial and economic development of the Auvergne-Rhône-Alpes region and will help create employment. All the stakeholders of the project as well as their R&D and industrial activities are based in this region.
BIOCORP
biocorpsys.com
Aguettant
aguettant.com
